Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Angiogenesis is crucial for tumor survival, growth, and metastasis.
• Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) are key regulators of angiogenesis.
• Targeting angiogenesis presents a therapeutic strategy for cancer treatment.

Purpose of the Study:

• To evaluate a novel nanobody designed to inhibit VEGFR2.
• To assess the nanobody's ability to retain VEGFR2 within the endoplasmic reticulum.
• To determine if this intracellular retention prevents VEGFR2 transport to the cell membrane.

Main Methods:

• A nanobody sequence was fused with green fluorescent protein and a KDEL retention signal.
• The construct was cloned into a mammalian expression vector.
• 293KDR cells were transfected, and VEGFR2 surface localization was analyzed via flow cytometry.

Main Results:

• The novel nanobody effectively targeted the VEGFR2 receptor intracellularly.
• Surface expression of VEGFR2 on transfected cells was significantly reduced.
• The nanobody demonstrated successful retention of VEGFR2 within the endoplasmic reticulum.

Conclusions:

• The developed nanobody is a potent tool for downregulating surface-expressed target proteins like VEGFR2.
• This intracellularly acting nanobody has potential as a therapeutic agent to inhibit tumor growth.
• The strategy of intracellular nanobody targeting offers a novel approach for cancer therapy.